 PRINCETON, N.J. DEERFIELD, Ill.BUSINESS WIREOtsuka Pharmaceutical Co., Ltd. Otsuka and H. Lundbeck AS Lundbeck announce the U.S. Food and Drug Administration FDA has determined that the supplementary New Drug Application sNDA for brexpiprazole for the use in the treatment of agitation associated with Alzheimers dementia AAD is sufficiently complete to permit a substantive review. ... Otsuka and Lundbeck Announce FDA Acceptance and Priority Rev... 